Subtyping of advanced lung cancer based on PD-L1 expression, tumor histopathology and mutation burden (EGFR and KRAS): a study from North India

Subtyping of advanced lung cancer based on PD-L1 expression, tumor histopathology and mutation burden (EGFR and KRAS): a study from North India

Immune checkpoint inhibitor (PD-L1) therapy of advanced non-small-cell lung cancer (NSCLC) has variable outcomes. Tumor subtypes based on PD-L1 expression, histopathology, mutation burden is required for patient stratification and formulation of treatment guidelines. Lung cancers (n=57) diagnosed a...

Full description

Bibliographic Details
Main Authors: Ritu Kulshrestha, Himanshi Saxena, Raj Kumar, Sonam Spalgius, Parul Mrigpuri, Nitin Goel, Balakrishnan Menon, Meenu Rani, Pawan Mahor, Ishita Bhutani
Format: Article
Language:English
Published: PAGEPress Publications 2023-02-01
Series:Monaldi Archives for Chest Disease
Subjects:
Subtyping-lung cancer, PD-L1, coexisting EGFR/KRAS mutations, tumour histopathology, North India
Online Access:https://www.monaldi-archives.org/index.php/macd/article/view/2449

Internet

https://www.monaldi-archives.org/index.php/macd/article/view/2449

Similar Items